Morepen Laboratories enters US market with first ANDA filing for sitagliptin

Morepen Laboratories has filed its first ANDA with the US FDA for sitagliptin tablets across three different strengths, signalling the company's entry into integrated finished-dose development and regulatory operations in the United States market.

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, is widely used in diabetes management and represents a key therapeutic area for pharmaceutical companies seeking FDA approvals. The multi-strength formulation filing demonstrates Morepen's commitment to offering comprehensive treatment options to healthcare providers and patients in the US market.

This ANDA submission reflects Morepen's efforts to strengthen its presence in developed pharmaceutical markets by leveraging its manufacturing and regulatory expertise. The company has been progressively building its portfolio of finished-dose pharmaceutical products for global markets.

The filing also underscores the growing importance of the US market for Indian pharmaceutical manufacturers, who have established themselves as reliable suppliers of both active pharmaceutical ingredients and finished formulations. For Morepen, securing FDA approval for sitagliptin would enable the company to capture a share of the substantial American diabetes therapeutics market.

Regulatory approval timelines for ANDAs typically span 10 months to several years, depending on the complexity of the application and any additional information requests from the FDA. The company has not disclosed an expected approval timeline.